Actively Recruiting

Phase Not Applicable
Age: 18Years - 84Years
All Genders
NCT07347665

Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery

Led by Hyogo Medical University · Updated on 2026-02-24

200

Participants Needed

2

Research Sites

225 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.

CONDITIONS

Official Title

Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery

Who Can Participate

Age: 18Years - 84Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Acute cerebral infarction
  • Aged 18 to 84 years
  • NIH Stroke Scale score at admission 8 or higher
  • Prestroke modified Rankin Scale scores of 0-1 (able to carry out all usual activities)
  • Occlusion of the M2 segment of middle cerebral artery confirmed by digital subtraction angiography
  • ASPECTS or DWI-ASPECTS score 8 or higher
  • Ineligible for or failed intravenous tPA (no recanalization within 30 minutes after injection)
  • Randomization completed within 24 hours from last known well time
  • Endovascular therapy can be started within 30 minutes from randomization
  • Signed informed consent by patient or legally authorized representative
Not Eligible

You will not qualify if you...

  • Occlusion of anterior temporal artery, duplicate M1, or accessory M1
  • Occlusion of multiple major intracranial arteries
  • Difficulty in endovascular access due to tortuous vascular anatomy
  • Significant brain swelling with midline shift on CT or MRI
  • Known allergy more severe than skin rash to contrast agents
  • Evidence of acute intracranial hemorrhage on CT or MRI
  • Pregnant or potentially pregnant
  • Clinical evidence of chronic occlusion
  • High risk of hemorrhage (platelets less than 40,000/µl, APTT greater than 50 seconds, or PT-INR greater than 3.0)
  • Participation in another therapeutic investigational trial
  • Investigator judgment of non-compliance or uncooperativeness during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Hyogo Medical University

Nishinomiya, Hyōgo, Japan, 663-8501

Not Yet Recruiting

2

Hyogo Medical University

Nishinomiya, Hyōgo, Japan, 663-8501

Actively Recruiting

Loading map...

Research Team

K

Kazutaka Uchida, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here